Discovery and optimization of a novel series of liver X receptor-α agonists
摘要:
A novel series of hexafluorocarbinols were discovered as potent activators of the liver X receptor-alpha using a fluorescence polarization assay. Structure-activity relationship study led to the identification of compounds that are more potent agonists than the endogenous ligand, 24(S), 25-epoxycholesterol, with similar efficacy. Several compounds, including T0901317, were shown to have desirable pharmacokinetic profiles suitable for in vivo studies. (C) 2005 Elsevier Ltd. All rights reserved.
Discovery and optimization of a series of liver X receptor antagonists
作者:XianYun Jiao、David J. Kopecky、Ben Fisher、Derek E. Piper、Marc Labelle、Sharon McKendry、Martin Harrison、Stuart Jones、Juan Jaen、Andrew K. Shiau、Patrick Escaron、Jean Danao、Anne Chai、Peter Coward、Frank Kayser
DOI:10.1016/j.bmcl.2012.07.048
日期:2012.9
The present report describes our efforts to convert an existing LXR agonist into an LXR antagonist using a structure-based approach. A series of benzenesulfonamides was synthesized based on structural modification of a known LXR agonist and was determined to be potent dual liver X receptor (LXR alpha/beta) ligands. Herein we report the identification of compound 54 as the first reported LXR antagonist that is suitable for pharmacological in vivo evaluation in rodents. (C) 2012 Published by Elsevier Ltd.